Patheon OneSource™ helps small and emerging pharmaceutical companies lower risk and drive more predictable outcomes by integrating drug substance and drug product development decisions within a single CDMO.
Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services. We provide a comprehensive, integrated and highly customizable range of active pharmaceutical ingredient, or API, and finished drug product services to our customers. From formulation development to clinical and commercial-scale manufacturing, packaging, and life cycle management, our services support both small molecule and large molecule drugs. We believe we are the only end-to-end integrated provider of such services, which, combined with our scientific and regulatory expertise and specialized capabilities, allows our customers to work with an outsourcing partner to address their most complex development and manufacturing needs.
Through the company’s end-to-end integrated service offering, known as “Patheon OneSource™,” clients have access to comprehensive solutions for both small and large molecule drugs across Patheon’s three main segments, including development and manufacturing services for API (Drug Substance Services, or DSS), formulation development and pre-clinical and clinical drug product manufacturing (Pharmaceutical Development Services, or PDS), and commercial drug product manufacturing and packaging (Drug Product Services, or DPS).
Over the last 10 years, Patheon has supported the delivery of 112 NDA-approved drugs - more than 2.5x the nearest competitor, and as many as the next six leading CMOs combined. A Healthier World. Delivered.
Company name: Patheon
Website: http://www.patheon.com
E-mail: doingbusiness@patheon.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.